Seeking Partners for a Bispecific Antibody Targeting IL4Rα/IL13 and IL31 for Atopic Dermatitis | DrugTimes BD Project

In the early clinical development of atopic dermatitis (AD), multiple inflammatory factors have been explored. However, in recent years, only a few monoclonal antibodies have been approved for AD treatment, including Dupilumab, Tralokinumab, Lebrikizumab, and Nemolizumab. Among them, Dupilumab, a representative drug targeting the IL-4/IL-13 axis, has emerged as a breakthrough therapy.

Dupilumab was the first targeted biologic approved for moderate-to-severe AD in adults and adolescents, with subsequent approvals in multiple countries and regions worldwide. Starting with the AD indication, Dupilumab has expanded its therapeutic reach to asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis (PN), and chronic obstructive pulmonary disease (COPD), demonstrating broad clinical potential and significant market value. In 2024, Dupixent achieved annual sales of €13.072 billion, positioning itself as the next “blockbuster drug” in autoimmune therapeutics, following adalimumab (Humira).

The vast AD market has also attracted the attention of Johnson & Johnson (J&J). In May 2024, J&J acquired Yellow Jersey Therapeutics for $1.25 billion, gaining access to its bispecific antibody NM26-2198, which simultaneously targets IL-4Rα and IL-31. Dupilumab has already validated the therapeutic value of IL-4Rα inhibition in alleviating AD-related inflammation, while Nemolizumab has confirmed the role of IL-31R blockade in reducing AD-associated pruritus. Building on this scientific foundation, NM26-2198 is expected to simultaneously suppress inflammation and pruritus signaling through its dual-targeting mechanism, thereby more effectively disrupting the “itch-scratch cycle” and improving patients’ quality of life.

The DrugTimes BD team is currently assisting in seeking partners for a preclinical bispecific antibody targeting IL4Rα/IL13 and IL31.

Project Brief

Project Code: DT-20250513-049

Project Name: A Bispecific Antibody Targeting IL4Rα/IL13 and IL31 for Atopic Dermatitis

Indication: Atopic Dermatitis (AD)

Drug Type: Bispecific Antibody

Targets: IL4Rα / IL13, IL31

Development Stage: Preclinical

Key Highlights:

• Bispecific antibody simultaneously inhibiting IL4, IL13, and IL31.
• Simultaneous blockade of inflammation and pruritus through targeting of IL-4/IL-13 and IL-31 pathways
• DTC-049 is designed to provide a faster onset of efficacy and a potential larger effect size through the concomitant modulation of both pathways

Collaboration Mode: License-out (ex-China)

Contact us:

For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!